Criteria for holding and stopping IL2#

SystemRelative criteriaAbsolute criteria
CardiovascularSinus tachycardia 100-130 BPM*Sinus tachycardia > 130 BPM*
ECG indications of ischemia
Atrial fibrillation
Supraventricular tachycardia
Ventricular arrhythmias**
Elevated CKB-MB isoenzyme of troponin levels
DermatologicMoist desquamation
GastrointestinalDiarrhea, 1000 ml/shiftDiarrhea 1000 ml/shift x 2
Vomiting not responsive to medication
Ileus/abdominal distentionSevere abdominal distention affecting breathing
Bilirubin > 7 mg/dLSevere, unrelenting abdominal pain
Hemodynamic#*Maximum Phenylephrine 1-1.5 mcg/kg/minMaximum Phenylephrine 1.5-2.0 mcg/kg/min
Minimum Phenylephrine > 0.5 mcg/kg/minMinimum Phenylephrine > 0.8 mcg/kg/min
HemorrhagicSputum, emesis, or stool heme-positiveFrank blood in sputum, emesis, or stool
Platelets 30,000-50,000/mm3Platelets < 30,000 mm3
InfectiousStrong clinical suspicion or documented
MusculoskeletalWeight gain > 15%
Extreme tightnessExtreme paresthesias
NeurologicVivid dreamsHallucinations
Mild anxietyPersistent crying
Mental status changes not reversible in 2 hours
Unable to subtract serial "7 s" or spell "WORLD" backward
Disorientation
PulmonaryResting shortness of breath> 4 L O2 by nasal cannula or 40% by mask to maintain ≥ 95% O2 saturation
3- 4 L O2 by nasal cannula for O2 saturation ≥ 95%Intubation
Rales 1/3 up chestMoist rales ½ up chest
RenalUrine output 80-160 ml/shiftUrine < 80 ml/shift
Creatinine 2.5-2.9 mg/dLCreatinine ≥ 3 mg/dL
HCO3 ≤ 18 meq/dL

Abbreviations: BPM, beats per minute; ECG, electrocardiogram.

*Persistent at the time of dosing after correcting hypotension, fever, and tachycardia and discontinuing dopamine.

**Including premature ventricular contractions, bigeminy, and tachycardia.

#In order to maintain acceptable BP and pulse criteria.

*Phenylephrine Max is during the interval, Min at the time of dosing.

#The above criteria should be assessed at the scheduled time of next dose after aggressive measures to correct toxicity have been undertaken.

If ≤ 3 relative criteria, delay dosing, continue corrective measures and administer another dose if recovered in < 24 hours.

If >3 relative criteria or an absolute criteria are observed stop IL-2 for the current cycle.